Virus cocktail targets superbug pneumonia in first human test
NCT ID NCT07492771
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests MP101, a mix of two viruses that attack bacteria (phages), in 18 adults with Pseudomonas aeruginosa pneumonia. Participants receive a single dose of MP101 or a placebo alongside standard antibiotics. The main goal is to check safety and how the body handles the treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MP101 (a cocktail of two bacteriophages)
What this could lead to
If successful, this could point toward a new treatment option for hard-to-treat Pseudomonas pneumonia, especially when antibiotics fail.
What could go wrong
This is a very early, small phase 1 trial with only 18 participants. The main goal is safety, not effectiveness, and it may not work or have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA - BACTERIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance Hospital
Seoul, Seodaemun-gu, 03722, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••